Article
Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.
Experimental and clinical psychopharmacology - 1 Oct 2014
Kranzler Henry R, Feinn Richard, Gelernter Joel, Pond Timothy, Covault Jonathan
Abstract excerpt
Topiramate, which interacts with multiple neurotransmitter and enzyme systems, is approved by the Food and Drug Administration to treat seizure disorder, prevent migraine, and (in combination with phentermine) reduce weight. Topiramate has also been shown in multiple studies to reduce heavy drinking. The authors found that topiramate 200 mg/day significantly reduced heavy drinking in heavy drinkers with a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.